Several new therapies for metastatic colorectal cancer have been developed and refined, changing the way the disease can be treated.
This CME activity from ASCO 2012 reviews the results of the ongoing PACE (Ponatinib Ph+ ALL and CML Evaluation) trial.
This CME activity from ASCO 2012 reviews crizotinib in patients with ALK-positive non-small cell lung cancer.
This CME activity from ASCO 2012 describes the benefits of early palliative care in patients with metastatic cancer.
This CME activity from ASCO 2012 reviews carfilzomib, lenalidomide, and low-dose dexamethasone in patients with newly diagnosed multiple myeloma.
This CME activity reviews pomalidomide in combination with low-dose dexamethasone in patients with multiple myeloma refractory to lenalidomide, bortezomib, or both.
This CME activity from ASCO 2012 reviews abiraterone acetate plus prednisone in patients with asymptomatic and mildly symptomatic chemotherapy-naïve metastatic castration-resistant prostate cancer.